Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 30, 2003. The report details a specific corporate action regarding share re-purchases authorized by shareholders at the Annual General Meeting held on May 19, 2003.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share re-purchase transaction:
- Shares Purchased: 750,000 ordinary shares
- Purchase Price: 1,239.716p per share
- Transaction Purpose: Cancellation of shares
Material Changes
The filing does not report material changes in operating results or financial position compared to prior periods. The primary event is the reduction of the company's share capital through the cancellation of 750,000 shares.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. The document is strictly a notification of the share re-purchase execution.
Investor Verification Points
- Verify the total number of shares authorized for re-purchase at the May 19, 2003 AGM to determine remaining capacity.
- Confirm the total cash outflow for this specific transaction (750,000 shares x 1,239.716p).
- Check subsequent filings for the impact of share cancellation on earnings per share (EPS) and total share count.